A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

NCT06508216 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Dato-DXd
DRUG: Durvalumab

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]